Cited by 255Estrogen and related hormone effectsBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

The DOI matches its Crossref record.

Estrogen Receptors as Therapeutic Targets in Breast Cancer

Ariazi, Eric, Ariazi, Jennifer, Cordera, Fernando, Jordan, V.·2006·Current Topics in Medicinal Chemistry

Open this paper in CoChat — free account

Abstract

The estrogen receptor α (ERα) has proven to be the single most important target in breast cancer over the last 30 years. The use of the selective ER modulator (SERM) tamoxifen for the treatment and prevention of breast cancer has changed therapeutics. The SERM raloxifene, approved for the treatment of osteoporosis, lacks tamoxifens increased risk for endometrial cancer and is being evaluated for the prevention of breast cancer. Other SERMs approved or under development for use against breast cancer or osteoporosis include toremifene, GW5638, GW7604 (the active metabolite of GW5638), idoxifene, lasofoxifene, arzoxifene, bazedoxifene, EM-800 and acolbifene (the active metabolite of EM- 800). Aromatase inhibitors (AIs) have recently proven to be more efficacious than tamoxifen as first-line therapy, efficacious for second-line therapy (e.g. against tamoxifen-resistant disease), and useful for extended adjuvant therapy after tamoxifen. The AIs include the non-steroidal agents letrozole and anastrole, and the steroidal agent exemestane. The pure antiestrogen fulvestrant has proven to be just as effective as AIs. Other pure antiestrogens, ZK-703, ZK-253, RU 58668 and TAS-108 show great promise. The development of resistance to endocrine therapy remains a clinically important problem, and laboratory models based on human breast cancer cells grown as tumors in immune-compromised mice have led to important insights into this problem. Progesterone receptor-negative status of ER-positive breast cancers may reflect altered growth factor receptor signaling, and helps to explain why this subclass of tumors exhibits lower response rates to tamoxifen compared to cancers typed progesterone receptor-positive. Crosstalk among plasma membrane-localized ER, growth factor receptor signaling, and nuclear-localized ER provide further insights into antihormonal-resistant breast cancer. Keywords: Estrogen receptor, selective estrogen receptor modulator, aromatase inhibitor, pure antiestrogen, breast cancer, antihormonal resistance

Integrity signals

Registry

Crossref · 10.2174/156802606776173483

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
G-protein-coupled receptors and cancer
Dorsam, R. T., & Gutkind, J. S. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2069 · Cited by 1,448
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,280
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
In vivo effects of a GPR30 antagonist
Dennis, M. K., Burai, R., Ramesh, C., Petrie, W. K., Alcon, S. N., Nayak, T. K., Bologa, C., Leitão, A., Brailoiu, E., Deliu, E., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.168 · Cited by 533
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 522
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women
Morrison, J. H., Brinton, R. D., Schmidt, P. J., & Gore, A. C. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3369-06.2006 · Cited by 406
The unfolding stories of GPR30, a new membrane-bound estrogen receptor
Maggiolini, M., & Picard, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0242 · Cited by 360
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
Rao, X., Leva, G. D., Li, M., Fang, F., Devlin, C. M., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P. (2010) · Oncogene · doi:10.1038/onc.2010.487 · Cited by 348
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11579 · Cited by 309
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Thangavel, C., Dean, J. L., Ertel, A., Knudsen, K. E., Aldaz, C. M., Witkiewicz, A. K., Clarke, R., & Knudsen, E. S. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0262 · Cited by 302
Activation of the Glucocorticoid Receptor Is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer
Pan, D., Kocherginsky, M., & Conzen, S. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0362 · Cited by 310
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 303
Canine tumors: a spontaneous animal model of human carcinogenesis
Pinho, S. S., Carvalho, S., Cabral, J., Reis, C. A., & Gärtner, F. (2011) · Translational research · doi:10.1016/j.trsl.2011.11.005 · Cited by 298
Anticancer steroids: linking natural and semi-synthetic compounds
Salvador, J. A. R., Carvalho, J. F. S., Neves, M. A. C., Silvestre, S., Leitão, A. J., Silva, M. M., & Melo, M. L. S. E. (2012) · Natural Product Reports · doi:10.1039/c2np20082a · Cited by 283
Estrogen-Receptor Expression and Function in Female Reproductive Disease
Tang, Z.-R., Zhang, R., Lian, Z., Deng, S., & Yu, K. (2019) · Cells · doi:10.3390/cells8101123 · Cited by 278
International Union of Basic and Clinical Pharmacology. XCVII. G Protein–Coupled Estrogen Receptor and Its Pharmacologic Modulators
Prossnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 269
ERRα: a metabolic function for the oldest orphan
Villena, J. A., & Kralli, A. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.07.005 · Cited by 252
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Lai, A. G., Kahraman, M., Govek, S. P., Nagasawa, J. Y., Bonnefous, C., Julien, J., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 253
A genome-wide atlas of co-essential modules assigns function to uncharacterized genes
Wainberg, M., Kamber, R. A., Balsubramani, A., Meyers, R. M., Sinnott-Armstrong, N., Hornburg, D., Jiang, L., Chan, J., Jian, R., Gu, M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00840-z · Cited by 204
Selective estrogen receptor modulators: an update on recent clinical findings
Shelly, W., Draper, M. W., Krishnan, V., Wong, M., & Jaffe, R. B. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31816400d7 · Cited by 193
A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Samaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M. A., Smith, M. J., Browning, D. D., Rawson, J., Smith, S. B., Barrett, J. T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0447 · Cited by 190
MicroRNA-mediated drug resistance in breast cancer
Kutanzi, K. R., Yurchenko, O. V., Beland, F. A., Checkhun, V. F., & Pogribny, I. P. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0040-8 · Cited by 172
Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER
Prossnitz, E. R., & Barton, M. (2009) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.05.001 · Cited by 159
Estrogenic G protein‐coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin‐6 secretion via the MEK/ERK mitogen‐activated protein kinase pathway
He, Y., Cai, B., Yang, Y., Liu, X., & Wan, X. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01148.x · Cited by 158
RAD1901
Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000271 · Cited by 162
Targeting Akt3 Signaling in Triple-Negative Breast Cancer
Chin, Y. R., Yoshida, T., Marusyk, A., Beck, A. H., Polyák, K., & Toker, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2175 · Cited by 157
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis
Zou, Y., Tsai, W.-B., Cheng, C.-J., Hsu, C., Chung, Y. M., Li, P.-C., Lin, S.-H., & Hu, M. C. ‐. (2008) · Breast Cancer Research · doi:10.1186/bcr1872 · Cited by 155
The ins and outs of GPR30: A transmembrane estrogen receptor
Prossnitz, E. R., Oprea, T. I., Sklar, L. A., & Arterburn, J. B. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.03.006 · Cited by 149
Estrogen receptor β ligands: Recent advances and biomedical applications
Minutolo, F., Macchia, M., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2009) · Medicinal Research Reviews · doi:10.1002/med.20186 · Cited by 151
Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface
Leeuwen, I. J. D. V.-V., Pereira, D. D. C., Flach, K. D., Piersma, S. R., Haase, C., Bier, D., Yalçin, Z., Michalides, R. J. A. M., Feenstra, K. A., Jiménez, C. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220809110 · Cited by 148
The Serine Protease Inhibitor Protease Nexin-1 Controls Mammary Cancer Metastasis through LRP-1–Mediated MMP-9 Expression
Fayard, B., Bianchi, F., Dey, J. H., Moreno, E., Djaffer, S., Hynes, N. E., & Monard, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4573 · Cited by 142
Estrogen signaling: An emanating therapeutic target for breast cancer treatment
Saha, T., Makar, S., Swetha, R., Gutti, G., & Singh, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.023 · Cited by 144
Subcellular Localization of Sigma-2 Receptors in Breast Cancer Cells Using Two-Photon and Confocal Microscopy
Zeng, C., Vangveravong, S., Xu, J., Chang, K. C., Hotchkiss, R. S., Wheeler, K. T., Shen, D., Zhuang, Z., Kung, H. F., & Mach, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3803 · Cited by 119
DNA-Encoded Dynamic Chemical Library and Its Applications in Ligand Discovery
Zhou, Y., Li, C., Peng, J., Xie, L., Meng, L. H., Li, Q., Zhang, J., Li, X., Li, X., Huang, X., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09277 · Cited by 110
Aromatase inhibitors: Role in postmenopausal breast cancer
Kharb, R., Haider, K., Neha, K., & Yar, M. S. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000081 · Cited by 117
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer
Tang, C. C., Li, C., Zhang, S., Hu, Z., Wu, J., Dong, C., Huang, J., & Zhou, H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00099 · Cited by 113
GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer
Molina, L., Figueroa, C. D., Bhoola, K. D., & Ehrenfeld, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1350264 · Cited by 104
Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists
Chung, S., & Lambert, P. F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911436106 · Cited by 101
Estrogen-Related Receptor α1 Transcriptional Activities Are Regulated in Part via the ErbB2/HER2 Signaling Pathway
Ariazi, E. A., Kraus, R. J., Farrell, M. L., Jordan, V. C., & Mertz, J. E. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0227 · Cited by 100
Self-citation
Identification and Structure−Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms
Jain, N. F., Xu, J., Kanojia, R. M., Du, F., Jian-Zhong, G., Pacia, E., Lai, M.-T., Musto, A., Allan, G. F., Reuman, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900146e · Cited by 99
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance
Lin, X., Xiang, H., & Luo, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112689 · Cited by 104
p53, a Target of Estrogen Receptor (ER) α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells
Berger, C. E., Qian, Y., Liu, G., Chen, H.-W., & Chen, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.367326 · Cited by 93
RORα, a Potential Tumor Suppressor and Therapeutic Target of Breast Cancer
Du, J., & Xu, R. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215755 · Cited by 91
The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer
Capper, C. P., Rae, J. M., & Auchus, R. J. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0259-0 · Cited by 89
Stereoconvergent and -divergent Synthesis of Tetrasubstituted Alkenes by Nickel-Catalyzed Cross-Couplings
Zell, D., Kingston, C., Jermaks, J., Smith, S. R., Seeger, N., Wassmer, J., Sirois, L. E., Han, C., Zhang, H., Sigman, M. S., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08399 · Cited by 90
The miR-30 family: Versatile players in breast cancer
Yang, S., Yang, S.-Y., Wang, D., Chen, X., Shen, H.-Y., Zhang, X., Zhong, S., Tang, J.-H., & Zhao, J. (2017) · Tumor Biology · doi:10.1177/1010428317692204 · Cited by 81
PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
Sun, X., & Rao, Y. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00848 · Cited by 88
Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms
Delattin, N., Brucker, K. D., Vandamme, K., Meert, E. M. K., Marchand, A., Chaltin, P., Cammue, B. P. A., & Thevissen, K. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt449 · Cited by 81
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
Kahraman, M., Govek, S. P., Nagasawa, J. Y., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Liu, N., Lee, K., Aparicio, A. M., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00414 · Cited by 78
YAP inhibits ERα and ER+ breast cancer growth by disrupting a TEAD-ERα signaling axis
Li, X., Zhuo, S., Zhuang, T., Cho, Y. S., Wu, G., Liu, Y., Mu, K., Zhang, K., Su, P., Yang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30831-5 · Cited by 77
Antineoplastic Agents: Environmental Prevalence and Adverse Outcomes in Aquatic Organisms
Wormington, A. M., María, M. D., Kurita-Oyamada, H. G., Bisesi, J. H., Denslow, N. D., & Martyniuk, C. J. (2020) · Environmental Toxicology and Chemistry · doi:10.1002/etc.4687 · Cited by 72
Potentiation of ICI182,780 (Fulvestrant)-induced Estrogen Receptor-α Degradation by the Estrogen Receptor-related Receptor-α Inverse Agonist XCT790
Lanvin, O., Bianco, S., Kersual, N., Chalbos, D., & Vanacker, J.-M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704295200 · Cited by 72
Design and synthesis of ERα/ERβ selective coumarin and chromene derivatives as potential anti-breast cancer and anti-osteoporotic agents
Hussain, M. K., Ansari, M. I., Yadav, N., Gupta, P. K., Gupta, A. K., Saxena, R., Fatima, I., Manohar, M., Kushwaha, P., Khedgikar, V., et al. (2014) · RSC Advances · doi:10.1039/c3ra45749d · Cited by 73
Identification of Pyrido[1,2-α]pyrimidine-4-ones as New Molecules Improving the Transcriptional Functions of Estrogen-Related Receptor α
Peng, L., Gao, X., Duan, L., Ren, X., Wu, D., & Ding, K. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200976s · Cited by 73
1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor α
Xu, S., Zhuang, X., Pan, X., Zhang, Z., Duan, L., Liu, Y., Zhang, L., Ren, X., & Ding, K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003928 · Cited by 71
Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study
Adhikari, N., Amin, S. A., Saha, A., & Jha, T. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.041 · Cited by 72
Derrubone, an Inhibitor of the Hsp90 Protein Folding Machinery
Hadden, M. K., Galam, L., Gestwicki, J. E., Matts, R. L., & Blagg, B. S. J. (2007) · Journal of Natural Products · doi:10.1021/np070190s · Cited by 66
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69
Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells
Sundar, S. N., Marconett, C. N., Doan, V. B., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn214 · Cited by 61
The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm
López‐Tarruella, S., & Schiff, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1399 · Cited by 60
Intranuclear Drug Delivery and Effective in Vivo Cancer Therapy via Estradiol–PEG-Appended Multiwalled Carbon Nanotubes
Das, M., Singh, R. P., Datir, S. R., & Jain, S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4002409 · Cited by 59
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons
Wang, L., Guillen, V. S., Sharma, N., Flessa, K., Min, J., Carlson, K. E., Toy, W., Braqi, S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00106 · Cited by 61
TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer
May, F. E. B., & Westley, B. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0129 · Cited by 53
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin
Jandial, D., Krill, L. S., Chen, L., Wu, C., Ke, Y., Xie, J., Hoang, B. H., & Zi, X. (2017) · Molecules · doi:10.3390/molecules22030462 · Cited by 53
15-Deoxy-Δ12,14-Prostaglandin J2 Inhibits Transcriptional Activity of Estrogen Receptor-α via Covalent Modification of DNA-Binding Domain
Kim, H., Kim, J., Meng, Z., Wang, L. H., Liu, F., Conrads, T. P., Burke, T. R., Veenstra, T. D., & Farrar, W. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3043 · Cited by 50
In Silico Docking Studies of Selected Flavonoids - Natural Healing Agents against Breast Cancer
Suganya, J., Mahendran, R., Naorem, L. D., & Marimuthu, N. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.19.8155 · Cited by 52
Synthesis and Characterization of Iodinated Tetrahydroquinolines Targeting the G Protein-Coupled Estrogen Receptor GPR30
Ramesh, C., Nayak, T. K., Burai, R., Dennis, M. K., Hathaway, H. J., Sklar, L. A., Prossnitz, E. R., & Arterburn, J. B. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9011802 · Cited by 50
G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives
Pepermans, R. A., Sharma, G., & Prossnitz, E. R. (2021) · Cells · doi:10.3390/cells10030672 · Cited by 53
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
Mukhopadhyay, U. K., Oturkar, C. C., Adams, C., Wickramasekera, N. T., Bansal, S., Medisetty, R., Miller, A., Swetzig, W. M., Silwal‐Pandit, L., Børresen‐Dale, A., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz051 · Cited by 47
Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1
Kawamura, A., Westwood, I. M., Wakefield, L., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.12.012 · Cited by 46
Structure-Based Approach for the Study of Estrogen Receptor Binding Affinity and Subtype Selectivity
Salum, L. B., Polikarpov, I., & Andricopulo, A. D. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci8002182 · Cited by 46
Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies
Salum, L. D. B., Polikarpov, I., & Andricopulo, A. D. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.02.001 · Cited by 44
Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer cells
Gallo, D., Jacquot, Y., Laurent, G., et al. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.04.011 · Cited by 42
Molecular Modeling Evaluation of Non‐Steroidal Aromatase Inhibitors†
Narayana, B. L., Deb, P. K., Balakumar, C., Rao, K. V., Kaur, R., Akkinepally, R. R., Murthy, J. N., & Ravikumar, M. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01277.x · Cited by 42
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
Nagasawa, J. Y., Govek, S. P., Kahraman, M., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., Aparicio, A. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00921 · Cited by 44
Surface Chemistry Dependent “Switch” Regulates the Trafficking and Therapeutic Performance of Drug-Loaded Carbon Nanotubes
Das, M., Singh, R. P., Datir, S. R., & Jain, S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300598z · Cited by 41
Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer
Zhang, X., Wang, Y., Li, X., Wu, J., Zhao, L., Li, W., & Liu, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00280 · Cited by 48
Integrated approach for studying bioactive compounds from Cladosporium spp. against estrogen receptor alpha as breast cancer drug target
Anandan, S., Gowtham, H. G., Shivakumara, C. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22038-x · Cited by 40
Genetically engineered ERα-positive breast cancer mouse models
Dabydeen, S. A., & Furth, P. A. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0512 · Cited by 40
Synthesis of targeted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity
Ansari, M. I., Hussain, M. K., Arun, A., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.035 · Cited by 40
Response of Estrogen Receptor-Positive Breast Cancer Tumorspheres to Antiestrogen Treatments
Ao, A. S., Morrison, B. J., Wang, H., López, J. A., Reynolds, B. A., & Lu, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018810 · Cited by 39
Tamoxifen inhibits migration of estrogen receptor‐negative hepatocellular carcinoma cells by blocking the swelling‐activated chloride current
Mao, J., Yuan, J., Wang, L., Zhang, H., Jin, X., Zhu, J., Li, H., Xu, B., & Chen, L. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24245 · Cited by 39
Modification of gene expression induced by siRNA targeting of estrogen receptor α in MCF7 human breast cancer cells
Luqmani (1992) · International Journal of Oncology · doi:10.3892/ijo_00000145 · Cited by 38
Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents
Tang, Z., Wu, C.-Z., Wang, T., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.029 · Cited by 38
Transcriptional cross talk between orphan nuclear receptor ERR and transmembrane transcription factor ATF6 coordinates endoplasmic reticulum stress response
Misra, J., Kim, D.-K., Choi, W., Koo, S., Lee, C.-H., Back, S.-H., Kaufman, R. J., & Choi, H.-S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt429 · Cited by 39
Estrogen receptor (ER) and ER-related receptor expression in normal and atrophic human vagina
Cavallini, A., Naro, E. D., Giocolano, A., et al. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.01.004 · Cited by 37
Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing
Yanagawa, T., Kagara, N., Miyake, T., Tanei, T., Naoi, Y., Shimoda, M., Shimazu, K., Kim, S. J., & Noguchi, S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4190-z · Cited by 36
Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study
Li, X., Lu, J., Zhang, L., Luo, Y., Zhao, Z., & Li, M. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.11.007 · Cited by 40
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids
Mendoza‐Sanchez, R., Cotnoir‐White, D., Kulpa, J., Jutras, I., Pottel, J., Moitessier, N., Mader, S., & Gleason, J. L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.11.005 · Cited by 37
Design and synthesis of bisubstrate inhibitors of type 1 17β-hydroxysteroid dehydrogenase: Overview and perspectives
Fournier, D., Poirier, D., Mazumdar, M., & Lin, S. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.01.044 · Cited by 34
Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha
Lin, W., Huang, J., Liao, X., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.044 · Cited by 33
Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer
Makar, S., Saha, T., Swetha, R., Gutti, G., Kumar, A., & Singh, S. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103380 · Cited by 34
Physalis peruviana-Derived Physapruin A (PHA) Inhibits Breast Cancer Cell Proliferation and Induces Oxidative-Stress-Mediated Apoptosis and DNA Damage
Yu, T., Cheng, Y., Lin, L., et al. (2021) · Antioxidants · doi:10.3390/antiox10030393 · Cited by 33
Combinatorial drug approaches to tackleCandida albicansbiofilms
Cremer, K. D., Staes, I., Delattin, N., Cammue, B. P. A., Thevissen, K., & Brucker, K. D. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1056162 · Cited by 31
Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes
Bertini, S., Cupertinis, A. D., Granchi, C., Bargagli, B., Tuccinardi, T., Martinelli, A., Macchia, M., Gunther, J. R., Carlson, K. E., Katzenellenbogen, J. A., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.030 · Cited by 30
DNA aptamer probes for detection of estrogen receptor α positive carcinomas
Sett, A., Borthakur, B. B., Sharma, J. D., et al. (2016) · Translational research · doi:10.1016/j.trsl.2016.12.008 · Cited by 30
Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader
Zhao, Y., Zhao, C., Lu, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104294 · Cited by 29
Crosstalk between non-coding RNAs expression profile, drug resistance and immune response in breast cancer
Miraghel, S. A., Ebrahimi, N., Khani, L., Mansouri, A., Jafarzadeh, A., Ahmadi, A., & Aref, A. R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106041 · Cited by 29

Authors: Ariazi, E., Ariazi, J., Cordera, F., & Jordan, V.
ORCID: Cordera, Fernando
Venue: Current Topics in Medicinal Chemistry
Publisher: Bentham Science Publishers Ltd.
Published: 2006-02-01
Volume: 6
Issue: 3
Pages: 181-202
ISSN: 1568-0266 (ISSN-L)
DOI: 10.2174/156802606776173483
OpenAlex: W4254152438
Cited by: 255
References: 0
Citations by year: 2026: 4 · 2025: 9 · 2024: 9 · 2023: 18 · 2022: 16 · 2021: 19 · 2020: 9 · 2019: 14 · 2018: 15 · 2017: 11 · 2016: 13 · 2015: 14 · 2014: 9 · 2013: 12 · 2012: 8
FWCI: 10.82
Type: journal article
Language: en
Open access: closed
Locations: Current Topics in Medicinal Chemistry (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: estrogen receptor alpha, breast cancer, selective estrogen receptor modulators, tamoxifen, raloxifene, aromatase inhibitors, fulvestrant, endocrine therapy resistance, progesterone receptor-negative breast cancer, growth factor receptor signaling, breast cancer prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Estrogen Receptors as Therapeutic Targets in Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks